Medical-focused Hatteras Venture Partners said today it closed its 5th life sciences fund, the Hatteras Venture Partners V fund, with over $150 million in capital.
The group said it aims to use the fund to invest in seed and early stage companies in the human medicine life sciences industry. A portion of the fund will be allocated to its Hatteras Discovery biz to “expand its successful model of company formation.”
Research Triangle Park, N.C.-based Hatteras Ventures invests in biopharmaceutical, medical device, diagnostics and health IT companies, with a particular focus in the southeastern US.
“We are gratified to have surpassed our $150 million target for HVP V. New and existing limited partners have exceeded our expectation in affirming our hands-on model of company formation and development,” general partner Clay Thorp said in prepared remarks.